Intravenous r-TPA in vertebrobasilar acute infarcts

Neurology. 2004 May 25;62(10):1854-6. doi: 10.1212/01.wnl.0000125330.06520.0d.

Abstract

Presented are the clinical data of 18 consecutive patients who were treated by IV recombinant tissue plasminogen activator (r-TPA) for suspected vertebrobasilar (VB) acute ischemia within 7 hours. The mean delay for treatment was 5 +/- 3.6 hours. Mean baseline NIH Stroke Scale score was 17 +/- 4. At 3 months, 10 patients were independent (modified Rankin Scale [mRS] score = 0 to 2), whereas 8 patients showed a poor outcome (mRs = 3 to 6). IV r-TPA in VB ischemia in a 7-hour window may be safe and efficient.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anticoagulants / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Fibrinolytic Agents / therapeutic use*
  • Heparin / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Nadroparin / therapeutic use
  • Platelet Aggregation Inhibitors / therapeutic use
  • Recombinant Proteins / therapeutic use
  • Severity of Illness Index
  • Thrombolytic Therapy*
  • Tissue Plasminogen Activator / therapeutic use*
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vertebrobasilar Insufficiency / diagnostic imaging
  • Vertebrobasilar Insufficiency / drug therapy*

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Nadroparin
  • Platelet Aggregation Inhibitors
  • Recombinant Proteins
  • Heparin
  • Tissue Plasminogen Activator